Type I diabetes (T1D) is a complex disorder, which arises from the autoimmune destruction of the insulin-secreting b cells of the pancreas leading to a life-long dependence on exogenous insulin. A recent study of T1D cases and controls provided evidence for association between an allele of a functional single-nucleotide polymorphism (SNP) in the PTPN22 gene and T1D. In the current study, this SNP was genotyped in a collection of 406 multiplex T1D families. Significant evidence of the combined presence of association and linkage to T1D was obtained (P ¼ 2.5 Â 10 À5 ). Linkage studies in subsets of families defined by PTPN22 SNP genotypes suggest possible interaction with loci on chromosomes 3 and 21. Previous genome scans in this collection of T1D families, and others, have not yielded significant evidence of linkage in the region of the PTPN22 locus. However, the highly significant evidence of allelic association suggests that variation at, or near, this functional SNP contributes to the risk of T1D.
Introduction
Type I diabetes (T1D) results from autoimmune destruction of the b cells of the pancreas, disrupting glucose homeostasis by eliminating the sole source of insulin for the body. The increased concordance rates for T1D in monozygotic, as opposed to dizygotic, twins as well as the tendency for the disorder to aggregate within families all suggest that a portion of the risk for T1D is inherited. 1, 2 Considerable effort has been expended in attempting to identify genetic risk factors for T1D with the potential goals of developing predictive tools and better understanding the underlying etiology of the disorder, particularly during the preclinical phase. 3, 4 More than 1000 multiplex T1D families have been studied by genome scans for evidence of linkage to T1D. [5] [6] [7] [8] [9] Although these linkage approaches have detected loci with demonstrable effects on familial clustering of T1D, the modest sibling risk ratios (eg, lsr1.3) predicted for several of these loci suggest that prohibitively large numbers of families may be required to derive a complete description of genetic risk for T1D from linkage studies alone. An alternative to linkage studies is direct investigation of candidate genes or single-nucleotide polymorphisms (SNPs) for allelic association with T1D in either a case-control or family-based design. While many of these studies, particularly when performed in a case-control format, have suffered from poor reproducibility, they have resulted in the identification and characterization of several well-accepted T1D susceptibility loci such as the HLA region on chromosome 6p, 10 the insulin gene region on chromosome 11p, 11 and the CTLA4 gene region on chromosome 2q. 12, 13 Furthermore, given the autoimmune etiology of T1D, it is not surprising that these identified loci and many of the candidate genes studied are predicted to have effects on the specificity or activation of the immune response. Three recent reports suggest that an SNP in the PTPN22 gene, which encodes the 110 kDa lymphoidspecific phosphatase (Lyp) on chromosome 1p13, may be associated with autoimmunity. [14] [15] [16] Lyp plays a key role as a negative regulator of T-cell activation by dephosphorylating T-cell receptor activation-dependent kinases. 17, 18 A nonsynonymous SNP at position 1858 (rs2476601) in the coding sequence of PTPN22 results in a change at codon 620 from arginine (CGG) to a tryptophan (TGG). This change likely affects the ability of Lyp to interact with the Csk kinase in vivo since reduced levels of Csk are co-immunoprecipitated from cell lines by the 620W variant as compared to the 620R form. 14 Bottini et al 14 reported that the 1858T (620W) allele in the PTPN22 gene was observed more frequently in T1D cases compared to controls in subjects from North America and from Sardinia. Begovich et al 15 reported that the same allele at this SNP was associated with rheumatoid arthritis (RA) in two separate case-control studies from North America. Kyogoku et al 16 found that the 1858T (620W) allele was also associated with increased risk of systemic lupus erythematosis (SLE).
Results and discussion
The 1858C/T SNP in the PTPN22 gene was genotyped in 406 T1D-affected sib pair families from the Human Biological Data Interchange (HBDI) repository. 19 The families genotyped were all collected within the US and were of European ancestry. Healthy siblings, where available, were included in the analysis as controls. A total of 1960 individuals were genotyped. Independent, blinded genotyping was carried out on the same set of samples using two different methodologies, the MGBEclipse system (Epoch Biosciences) and the Taqman system (Applied Biosystems, Inc.). The concordance rate between the two methods for genotypes was extremely high (99.6%); genotypes for the small number of samples yielding discrepant results were resolved by sequencing.
The multipoint evidence for linkage to T1D in families at the PTPN22 locus was modest (LOD ¼ 0.75). The predicted l s for PTPN22 was 1.23. The allele frequency for the putative risk allele, 1858T, estimated from founder genotypes, was 0.12 (95% CI ¼ 0.099-0.14). In order to test for association between this allele and T1D, the pedigree disequilibrium test (PDT) was used, which tests for association in families where there is genotype data from more then one affected sib. 20 The 1858T allele was preferentially transmitted to affected offspring from heterozygote parents (w 2 ¼ 17.8, P ¼ 2.5 Â 10
À5
). Transmissions of the 1858T allele to healthy siblings, at 44.7%, were slightly reduced from the expected 50%, but not significantly so.
The DNA samples from families used for the current analysis have previously been studied by genome-wide scan with microsatellite markers, 7, 8 as well as by HLA typing, allowing exploratory analyses for possible interaction between PTPN22 and other loci in the genome. A comparison of the transmission of HLA haplotypes between affected offspring homozygous for the 1858C allele and those either heterozygous or homozygous for the 1858T allele revealed no significant differences in transmission ratio.
The subset of families carrying the 1858T allele may represent a distinct population in terms of T1D pathogenesis. Therefore, linkage analysis within this subset might reveal evidence for interacting loci that are not apparent when collections of multiplex T1D pedigrees are analyzed in bulk. Taking advantage of existing genome scan data, linkage analyses were carried out using two sets of families. The first consisted of the 406 HBDI families genotyped for the PTPN22 SNP to establish the baseline evidence for linkage to T1D in the complete sample. The second, a subset of the first, consisted of 58 families where each of the two affected sibs carried the 1858T (620W) allele. For most of the genome, differences between the baseline and subset LODs were proportional to the differences in samples size. However, at two locations, on chromosomes 3 and 21, the LOD in the 1858T subset substantially exceeded the baseline LOD (Figure 1 ). On chromosome 21 at 9.03 cM (between markers D21S172 and D21S1437), the baseline LOD was 0.01, while in the subset of families where the ASPs shared the 1858T allele the LOD was 2.07. On chromosome 3 at 86.8 cM (between markers D3S1312 and D3S4542), the baseline LOD was 0.22 and the LOD in the 1858T sharing subset was 1.76. To assess the significance of these increases in LOD score over baseline, simulations were carried out in which random subsets of 58 families were selected and analyzed for linkage to T1D at the indicated positions. For each of these sites, there was some empiric evidence of interaction (chromosome 3: P ¼ 0.004, chromosome 21: P ¼ 0.001). However, these findings did not attain a genome-wide significance level and should be treated with due caution.
Based on functional studies, the 1858T (620W) allele is predicted to act as a loss of function variant, lowering the threshold for T-cell receptor-dependent activation, possibly through reduced interaction with Csk. Homozygotes for the risk allele might be expected to have a more severe or rapid onset of disease. In the case of SLE, Figure 1 Evidence for linkage to T1D on chromosomes 3 and 21 conditional on PTPN22 SNP genotype. Multipoint linkage analysis was conducted using the S-pairs scoring function in Genehunter Plus and genotype data from Mein et al. 6 Maximized LOD scores were calculated using an exponential model with d constrained between 0 and 2. 21 For stratified analysis, individual families were given weights of 1 or 0 and the LOD scores were recalculated using these assigned weights. 'Baseline' indicates the LOD in all families (N ¼ 406) genotyped for the PTPN22 SNP. '1858T' indicates the LOD in the subset of 58 families in which affected sibs shared the 1858T allele identical by state.
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16 reported a dosage effect with homozygotes for the 1858T allele having approximately twice the risk of heterozygotes. When the age at onset for individuals homozygous for the 1858T allele (N ¼ 12) was compared to the age at onset for affected 1858C homozygotes selected randomly from the T1D families genotyped here, there was a marginally significant difference in the distribution (P ¼ 0.048). The median age at onset for 1858T homozygotes was 5.5 years, while for 1858C homozygotes it was 10 years. Homozygous 1858T individuals are infrequent, and larger numbers will need to be studied to determine if any trend towards earlier age at onset in this group can be confirmed.
In this study, a functional SNP in the PTPN22 gene, previously implicated in RA and SLE and T1D, was tested for linkage and association with disease in multiplex T1D families. The family-based method of association testing employed here is unaffected by population structure that can compromise case-control format studies and provided highly significant confirmation for the association of the PTPN22 1858T allele with T1D previously reported by Bottini et al.
14 The availability of full genome scan data for the families studied also allowed the exploratory tests for interaction between the PTPN22 SNP and other loci. These studies failed to reveal any significant evidence of interaction with previously established T1D loci, such as HLA, but suggested the possibility of interaction with novel loci located on chromosomes 3 or 21. An examination of these regions did not reveal any obvious candidate genes that might be implicated based on some known functional interaction between their products and Lyp. Whether this functional SNP in the PTPN22 gene is a causative variant for T1D, or simply a marker of other variation occurring nearby cannot be resolved by the current study. However, the highly significant findings suggest that further functional investigations of the Lyp protein, and a comprehensive study of variation in the PTPN22 gene are well justified.
